Merck KGaA strikes $3.9bn deal for SpringWorks
The deal follows months of market speculation and gives Merck access to two FDA-approved therapies.

The deal follows months of market speculation and gives Merck access to two FDA-approved therapies.
AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal
3 reasons why biotechs preparing for launch need a compliant content foundation
Google-backed Isomorphic Labs raises $600m to advance AI drug discovery
EU Health Data Space strikes a chord in EU harmonisation plans